Cancer Doesn't Have to be Found Late
Every year, thousands of Canadians are diagnosed with late-stage cancer — not because the cancer wasn’t detectable, but because the tools to detect it early enough didn’t exist. OncoSage
changes that.
Built on The Biology of Tumor-educated Platelets
OncoSage is built on the science of tumor-educated platelets (TEPs) — circulating cells that
carry a molecular signature of the disease they encounter. By reading the signal in TEPs from a routine blood sample, OncoSage can detect the presence, type, subtype, and stage of multiple cancers — without imaging or invasive procedures.
Built for Clinical Environments That Demand Accuracy
OncoSage combines cutting-edge biomarker science with AI-powered analysis to deliver four core clinical advantages.
-
Early Stage Detection
Designed to detect cancer at its earliest stages, when treatment is most effective and survival rates are highest.
-
Non-Invasive Blood Test
A standard clinical blood draw, performed in any clinical setting. No imaging, no biopsy, no specialized pre-analytical processing.
-
Rapid Turnaround
Results returned in clinically actionable timeframes, fitting into existing diagnostic workflows.
-
Type, Subtype, and Stage
Goes beyond a binary cancer / no-cancer answer — OncoSage delivers cancer type, subtype, and stage from a single sample.
From Blood Draw to Clinical Insight — Three Steps
01
Sample Collection
A standard blood draw is collected and shipped to the OncoSage laboratory.
02
Analysis
TEPs are isolated and analyzed using OncoSage’s proprietary platform.
03
Results Reporting
A clinically formatted report is delivered to the ordering clinician.
What Early Detection Means For You
A simple blood test could detect cancer before symptoms appear — when treatment is most effective and survival rates are highest. For patients and families, that means more options, less invasive treatment, and a better chance at long, healthy lives.
Designed for The Clinic
OncoSage fits into existing clinical workflows. The test uses a standard blood collection tube, requires no specialized handling, and returns results in a structured, clinically formatted report. For clinicians, this means earlier signal, fewer ambiguous diagnostic pathways, and a tool that complements — rather than replaces — existing screening modalities.
OncoSage vs. Conventional Screening
| Capability | Traditional Screening | OncoSage |
|---|---|---|
| Cancer types covered per test | Single cancer type | Multiple cancer types |
| Sample type | Imaging or invasive procedure | Standard blood draw |
| Special pre-analytical processing | Often required | None |
| Detection output | Cancer present or not present | Type, subtype, and stage |
| Patient burden | Moderate to high | Minimal |
Who OncoSage Is Built For
-
Clinicians and Oncologists
Order OncoSage as part of your diagnostic workflow.
-
Hospitals and Diagnostic Networks
Integrate OncoSage into your screening and early detection programs.
-
Patients and Families
Ask your clinician about OncoSage as part of an early detection plan.
-
Researchers and Partners
Collaborate with us on validation studies and clinical pilots.
See OncoSage in Action
Whether you’re a clinician, hospital administrator or researcher — book a personalised demo and see how OncoSage can integrate into your practice or programme.
Latest News and Insights
